Published Papers & Misc - TANAKA Shinji

181. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, Monte SD, Wands JR. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. Journal of Hepatology, 43:854-62, 2005 Journal of Hepatology, 43:854-62, 2005. 2005;

182. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. . Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M, Maehara Y. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. Journal of Clinical Oncology, 22:4165-73, 2004 Journal of Clinical Oncology, 22:4165-73, 2004. 2004;

183. Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. . Maehara Si, Tanaka S, Saito , Shirabe K, Maehara Y. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 112:184-9, 2004 International Journal of Cancer, 112:184-9, 2004. 2004;

184. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. . Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 127(4):1110-22, 2004 Gastroenterology, 127(4):1110-22, 2004. 2004;

185. Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. . Tanaka S, Sugimachi K, Kameyama T, Maehara Si, Shirabe K, Shimada M, Wands JR, Maehara Y. Human WISP1v, a member of CCN family, is associated with invasive cholangiocarcinoma. Hepatology, 37:1122-9, 2003 Hepatology, 37:1122-9, 2003. 2003;

186. Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. . Tanaka S, Sugimachi K, Maehara Si, Shimada M, Maehara Y. A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology, 125:1563-4, 2003 Gastroenterology, 125:1563-4, 2003. 2003;

187. Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Yamashita Yi, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K. Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology, 35:861-7, 2002 Hepatology, 35:861-7, 2002. 2002;

188. Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant WISPs as targets for gastrointestinal carcinomas. Gastroenterology, 123:392-3, 2002 Gastroenterology, 123:392-3, 2002. 2002;

189. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. . Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene, 20:5525-32, 2001 Oncogene, 20:5525-32, 2001. 2001;

190. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. . Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. Journal of Hepatology, 35:74-79, 2001 Journal of Hepatology, 35:74-79, 2001. 2001;

191. Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. . Etoh T, Inoue H, Tanaka S, Bernard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Cancer Research, 61:2145-2153, 2001 Cancer Research, 61:2145-2153, 2001. 2001;

192. Yamashita Yi, Shimada M, Hamatsu T, Rikimaru T, Tanaka S, Shirabe K, Sugimachi K. . Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Research. 2001; 61 1005-1012.

193. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. . Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR, Sugimachi K. Expression and anti-tumor effects of TRAIL in human cholangiocarcinoma. Hepatology, 32:523-527, 2000 Hepatology, 32:523-527, 2000. 2000;

194. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. Journal of Clinical Investigation, 103(3): 341-5, 1999 1999;

195. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, Ueo H, Takesako K, Akiyoshi T. Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunology and Immunotherapy, 48(4): 189-94, 1999 1999;

196. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. International Journal of Oncology, 15(4): 687-92, 1999 1999;

197. Shibata K, Tanaka S, Shiraishi T, Kitano S, Mori M. G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Research, 59(5): 1096-101, 1999 Cancer Research, 59(5): 1096-101, 1999. 1999;

198. Watanabe M, Kuwano H, Tanaka S, Toh Y, Sadanaga N, Sugimachi K. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus. Cancer, 85(11): 2322-8, 1999 1999;

199. Shimada M, Hasegawa H, Gion T, Shirabe K, Taguchi K, Takenaka K, Tanaka S, Sugimachi K. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology, 46(28): 2469-75, 1999 1999;

200. Watanabe M, Kuwano H, Tanaka S, Toh Y, Masuda H, Sugimachi K. A significant morphological transformation is recognized in human esophageal cancer cells with an amplification/overexpression of the Cyclin D1 gene. International Journal of Oncology, 15(6): 1103-1108, 1999 1999;